# EDIT — baseline

## Metadata

ticker: EDIT
arm: baseline
judge_prompt_version: v2
context_sha256: fd7ff8503c768b91434e04854654957cfc90635bb2edf9101c97ce5cf303e000
llm_calls: 7
llm_endpoints: anthropic
llm_by_site: {"rag:highlights": {"calls": 1, "completion_tokens": 342, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 3.978, "latency_s_total": 3.978, "parse_failure": 0, "prompt_tokens": 2492, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "rag:risks": {"calls": 1, "completion_tokens": 380, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 4.205, "latency_s_total": 4.205, "parse_failure": 0, "prompt_tokens": 2480, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:financial_health": {"calls": 1, "completion_tokens": 164, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.134, "latency_s_total": 2.134, "parse_failure": 0, "prompt_tokens": 638, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:recent_developments": {"calls": 1, "completion_tokens": 172, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.411, "latency_s_total": 2.411, "parse_failure": 0, "prompt_tokens": 631, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:risk_factors": {"calls": 1, "completion_tokens": 178, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 1.894, "latency_s_total": 1.894, "parse_failure": 0, "prompt_tokens": 453, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "section:sec_filing_highlights": {"calls": 1, "completion_tokens": 194, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 2.468, "latency_s_total": 2.468, "parse_failure": 0, "prompt_tokens": 423, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}, "synthesis": {"calls": 1, "completion_tokens": 1246, "completion_tokens_unrecorded": 0, "errors": 0, "format_failure": 0, "latency_s_max": 18.615, "latency_s_total": 18.615, "parse_failure": 0, "prompt_tokens": 1820, "prompt_tokens_unrecorded": 0, "repeat_run": 0, "retry": 0, "truncated": 0}}

## Retrieved source context

STOCK DATA:
{
  "ticker": "EDIT",
  "company_name": "Editas Medicine, Inc.",
  "current_price": 2.62,
  "currency": "USD",
  "market_cap": 402379680.0,
  "forward_pe": -3.4788148,
  "week_52_high": 4.537,
  "week_52_low": 1.66,
  "revenue": 47005000.0,
  "net_income": -73949000.0,
  "profit_margin": -1.57322,
  "sector": "Healthcare",
  "industry": "Biotechnology"
}

NEWS ARTICLES:
[
  {
    "title": null,
    "source": null,
    "published_at": null,
    "description": null
  }
]

SEC FILING SUMMARIES:
{
  "10-K": {
    "form_type": "10-K",
    "filing_date": "2026-03-09",
    "summary": "Item 1A. Risk Factors Our business is subject to numerous risks. The following important factors, among others, could cause our actual results to differ materially from those expressed in forward-looking statements made by us or on our behalf in this Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), press releases, communications with investors, and oral statements. Actual future results may differ materially from those anticipated in our forward-looking statements. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Risks Related to Our Financial Position and Need for Additional Capital We have incurred significant losses since inception. We expect"
  },
  "10-Q": {
    "form_type": "10-Q",
    "filing_date": "2026-08-05",
    "summary": "Item 1A. Risk Factors,\u201d as updated by our subsequent filings with the SEC. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make. You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q completely and with the understanding that our actual future results may be materially di"
  }
}

RAG — SEC HIGHLIGHTS:
[From Pinecone cache] # Key Takeaways from EDIT's SEC Filings

## Financial Position and Losses
- The company has accumulated significant operating losses totaling $1.6 billion as of December 31, 2025
- Net losses were $160.1 million (2025), $237.1 million (2024), and $153.2 million (2023)
- The company expects to continue incurring significant losses for the foreseeable future

## Funding and Capital Requirements
- Existing cash and cash equivalents as of December 31, 2025 are expected to fund operations into Q3 2027
- The company will need substantial additional funding to continue operations
- Primary funding sources include public equity offerings, debt financing, collaborations, and licensing arrangements
- Limited committed external funding sources exist, with contingent payments from BMS collaboration and Vertex license agreement being the only significant committed potential external sources

## Development Stage and Timeline
- The company is currently in preclinical testing stages for its most advanced research programs
- EDIT-401 is a key product candidate under development
- Commercial revenues are not expected for years, if at all
- Significant expenses are anticipated as the company progresses preclinical studies and clinical trials

## Risk Factors
- Inability to raise capital when needed could force delays or elimination of research and development programs
- Profitability achievement and sustainability remain uncertain
- Economic downturns or unfavorable political developments could impact the company's ability to raise capital and maintain operations
- Regulatory requirements could increase expenses beyond current expectations

RAG — RISK FACTORS:
[From Pinecone cache] # Primary Risk Factors Disclosed

The company discloses several significant risk factors, with the main categories being:

## Financial Position and Capital Needs
- **Substantial accumulated losses**: The company has incurred net losses of $160.1 million, $237.1 million, and $153.2 million for 2025, 2024, and 2023 respectively, with an accumulated deficit of $1.6 billion as of December 31, 2025.
- **Expectation of continued losses**: The company expects to incur losses for the foreseeable future and may never achieve profitability.
- **Significant funding requirements**: Substantial additional capital will be needed to continue operations, and if capital cannot be raised when needed, the company would be forced to delay, reduce, or eliminate research and development programs.
- **Limited funding runway**: Existing cash is expected to fund operations only into the third quarter of 2027.

## Development and Commercialization Challenges
- **Early-stage development**: The company is currently only in preclinical testing stages for its most advanced research programs, with years potentially needed before any product candidate is ready for commercialization.
- **Time-consuming and uncertain process**: Identifying product candidates and conducting preclinical testing and clinical trials is expensive and uncertain, with no guarantee of obtaining marketing approval or achieving product sales.
- **Commercialization expenses**: Significant costs will be incurred for sales, marketing, manufacturing, and distribution if marketing approval is obtained.

## Economic and Market Risks
- **Economic sensitivity**: Unfavorable economic conditions, political developments, or financial crises could adversely affect the company's ability to raise capital and could weaken demand for products if approved.

## Pre-written sections (judge input)

### Financial Health

Editas Medicine trades at $2.62 per share with a market capitalization of $402.4 million, reflecting significant financial distress for the biotechnology company. The company generated $47.0 million in revenue but posted a net loss of $73.9 million, resulting in a negative profit margin of -157.3%, indicating substantial cash burn. The negative forward P/E ratio underscores unprofitability, while the 52-week trading range of $1.66–$4.54 demonstrates considerable volatility. SEC filings highlight ongoing capital needs and accumulated losses since inception, positioning Editas as a pre-commercial or early-stage biotech firm dependent on external funding and pipeline success for viability.

### Recent Developments

Editas Medicine continues to face significant financial headwinds, with the company reporting a net loss of $73.9 million against modest revenue of $47 million, reflecting the substantial R&D investments required for gene-editing therapeutics development. The stock has declined substantially from its 52-week high of $4.54 to $2.62, indicating investor concerns about the company's path to profitability and capital requirements. Recent SEC filings highlight ongoing risks related to the company's financial position and need for additional capital, which remains a critical concern for shareholders. With a negative forward P/E ratio and continued operating losses, investors should monitor upcoming clinical trial results and partnership announcements as key catalysts that could validate the company's gene-editing platform and improve its financial trajectory.

### SEC Filing Highlights

Editas Medicine reported accumulated operating losses of $1.6 billion through December 31, 2025, with net losses of $160.1 million in 2025, and expects to continue incurring significant losses as it remains in preclinical and early-stage development. The company's existing cash position is projected to fund operations only through Q3 2027, necessitating substantial additional capital raises through equity offerings, debt financing, or strategic partnerships to sustain operations. With no near-term commercial revenues anticipated and only contingent payments from existing BMS and Vertex collaborations as committed external funding sources, Editas faces material capital adequacy risks that could force delays or elimination of R&D programs. The company's ability to achieve profitability remains highly uncertain and dependent on successfully advancing its pipeline candidates, particularly EDIT-401, through clinical development and regulatory approval.

### Risk Factors

- **Severe cash burn and limited runway**: Editas has accumulated losses of $1.6 billion and burned $160.1 million in 2025 alone, with existing cash expected to fund operations only through Q3 2027. The company expects continued losses and may never achieve profitability, creating substantial capital raising risk.

- **Early-stage development with uncertain timelines**: Most advanced programs remain in preclinical testing stages with years potentially required before commercialization. Clinical development is expensive and uncertain with no guarantee of regulatory approval or commercial success.

- **Dependence on capital markets**: The company requires substantial additional funding to continue operations. Unfavorable economic conditions or market disruptions could impair its ability to raise necessary capital, potentially forcing delays or elimination of R&D programs.

## Audited (Exec Summary + Outlook)

### Executive Summary
Editas Medicine is a clinical-stage gene-editing biotechnology company that has accumulated $1.6 billion in operating losses since inception, currently trading at $2.62 per share with a market capitalization of $402.4 million as it works to advance its CRISPR-based therapeutic pipeline toward commercialization. The stock is notable now because it sits near the lower end of its 52-week range of $1.66–$4.54, the company's cash runway extends only through Q3 2027, and the path to additional funding remains uncertain — creating a high-stakes environment where the margin for execution error is extremely narrow. The single most important near-term variable is whether Editas can generate clinical data from EDIT-401 compelling enough to attract a strategic partnership or support a capital raise on terms that do not severely dilute existing shareholders.

### Outlook
The directional lean on Editas Medicine is **cautious**, with the weight of evidence tilting toward meaningful downside risk absent a near-term catalyst. The primary headwinds are structural and pressing: a cash runway that expires in Q3 2027, a pattern of deep annual losses, and a pipeline that remains largely in preclinical or early clinical stages — leaving little room for trial setbacks or capital market disruptions. The key variables an investor should monitor are: (1) clinical data readouts from EDIT-401, which represent the most credible near-term proof point for the gene-editing platform; (2) the terms and timing of any new capital raise, since dilutive equity offerings at depressed prices would further pressure existing shareholders; (3) the evolution of the BMS and Vertex collaborations, where milestone or contingent payments could provide meaningful non-dilutive funding relief; and (4) the broader biotech funding environment, which will heavily influence Editas's ability to access capital on acceptable terms. What would shift this view toward a more constructive stance is a combination of positive EDIT-401 clinical data, a strategically structured partnership that extends the cash runway well beyond Q3 2027, and demonstrated moderation in the pace of cash burn. Conversely, a failed capital raise, disappointing clinical results, or deteriorating market conditions for early-stage biotech would deepen the already substantial concerns about the company's long-term viability.

---
*This brief is for informational purposes only and does not constitute financial advice.*

## Judge findings

I will now systematically evaluate every specific quantitative figure, price target, threshold, ratio, metric, percentage, named product milestone, or forward-looking number in the Executive Summary and Outlook sections.

---

**EXECUTIVE SUMMARY**

---

CLAIM: "accumulated $1.6 billion in operating losses since inception"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights and Risk Factors both explicitly state "accumulated operating losses totaling $1.6 billion as of December 31, 2025," and the SEC Filing Highlights pre-written section confirms this figure.

---

CLAIM: "currently trading at $2.62 per share"
LABEL: SUPPORTED
REASON: The stock data field "current_price" is explicitly $2.62.

---

CLAIM: "market capitalization of $402.4 million"
LABEL: SUPPORTED
REASON: The stock data field "market_cap" is $402,379,680, which rounds to $402.4 million.

---

CLAIM: "52-week range of $1.66–$4.54"
LABEL: SUPPORTED
REASON: The stock data explicitly lists "week_52_high": 4.537 (rounds to $4.54) and "week_52_low": 1.66, matching both bounds exactly.

---

CLAIM: "sits near the lower end of its 52-week range of $1.66–$4.54"
LABEL: SUPPORTED
REASON: Arithmetic check: the range spans $1.66 to $4.54 (width = $2.88); the midpoint is $3.10; $2.62 is below the midpoint and closer to the low ($0.96 above low vs. $1.92 below high), confirming it sits in the lower half of the range.

---

CLAIM: "cash runway extends only through Q3 2027"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly state "Existing cash and cash equivalents as of December 31, 2025 are expected to fund operations into Q3 2027," confirmed in both the Risk Factors and SEC Filing Highlights sections.

---

CLAIM: "EDIT-401" (named product milestone)
LABEL: SUPPORTED
REASON: EDIT-401 is explicitly named in the RAG SEC Highlights ("EDIT-401 is a key product candidate under development") and in the SEC Filing Highlights pre-written section.

---

**OUTLOOK**

---

CLAIM: "a cash runway that expires in Q3 2027"
LABEL: SUPPORTED
REASON: Directly stated in the RAG SEC Highlights and Risk Factors: "Existing cash and cash equivalents as of December 31, 2025 are expected to fund operations into Q3 2027."

---

CLAIM: "a pattern of deep annual losses" (directional/qualitative)
LABEL: SUPPORTED
REASON: The source data shows net losses of $160.1 million (2025), $237.1 million (2024), and $153.2 million (2023), confirming a multi-year pattern of deep annual losses.

---

CLAIM: "a pipeline that remains largely in preclinical or early clinical stages"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly state "The company is currently in preclinical testing stages for its most advanced research programs," and the Risk Factors confirm "Most advanced programs remain in preclinical testing stages."

---

CLAIM: "clinical data readouts from EDIT-401" (named product milestone as key variable)
LABEL: SUPPORTED
REASON: EDIT-401 is explicitly named as a key product candidate in the RAG SEC Highlights and SEC Filing Highlights sections.

---

CLAIM: "the BMS and Vertex collaborations, where milestone or contingent payments could provide meaningful non-dilutive funding relief"
LABEL: SUPPORTED
REASON: The RAG SEC Highlights explicitly name "contingent payments from BMS collaboration and Vertex license agreement" as "the only significant committed potential external sources" of funding.

---

CLAIM: "a strategically structured partnership that extends the cash runway well beyond Q3 2027"
LABEL: INFERENCE
REASON: The Q3 2027 runway figure is present in the source data; the claim that a partnership could extend it "well beyond" Q3 2027 is a logical forward-looking derivation from the stated runway endpoint, not an independently sourced figure, but it is fully derivable from the context without any absent facts.

---

CLAIM: "demonstrated moderation in the pace of cash burn" (as a condition for a more constructive view)
LABEL: INFERENCE
REASON: The source data documents the cash burn pattern ($160.1M in 2025, $237.1M in 2024, $153.2M in 2023); the claim that moderation in burn rate would be a positive signal is a logical directional inference from those figures, requiring no absent facts.

---

**Summary of Labels:**
- SUPPORTED: 11
- INFERENCE: 2
- UNSUPPORTED: 0
